459 related articles for article (PubMed ID: 16155016)
41. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
Chang H; Sloan S; Li D; Keith Stewart A
Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
[TBL] [Abstract][Full Text] [Related]
42. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
43. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.
Largo C; Alvarez S; Saez B; Blesa D; Martin-Subero JI; González-García I; Brieva JA; Dopazo J; Siebert R; Calasanz MJ; Cigudosa JC
Haematologica; 2006 Feb; 91(2):184-91. PubMed ID: 16461302
[TBL] [Abstract][Full Text] [Related]
44. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.
Bergsagel PL; Nardini E; Brents L; Chesi M; Kuehl WM
Curr Top Microbiol Immunol; 1997; 224():283-7. PubMed ID: 9308253
[TBL] [Abstract][Full Text] [Related]
45. Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
Tarsitano M; Palmieri S; Ferrara F; Riccardi C; Cavaliere ML; Vicari L
Cancer Genet Cytogenet; 2009 Dec; 195(2):164-7. PubMed ID: 19963117
[TBL] [Abstract][Full Text] [Related]
46. Acute myeloid leukemia (AML-M2) with t(5;11)(q35;q13) and normal expression of cyclin D1.
de Oliveira FM; Tone LG; Simões BP; Falcão RP; Brassesco MS; Sakamoto-Hojo ET; dos Santos GA; Marinato AF; Jácomo RH; Rego EM
Cancer Genet Cytogenet; 2007 Jan; 172(2):154-7. PubMed ID: 17213025
[TBL] [Abstract][Full Text] [Related]
47. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
[TBL] [Abstract][Full Text] [Related]
48. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
49. [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma].
Matsuda I; Mori Y; Nakagawa Y; Sawanobori M; Uemura N; Suzuki K
Rinsho Ketsueki; 2005 Dec; 46(12):1293-7. PubMed ID: 16447802
[TBL] [Abstract][Full Text] [Related]
50. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
51. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
52. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.
Yang C; Trent S; Ionescu-Tiba V; Lan L; Shioda T; Sgroi D; Schmidt EV
Cancer Res; 2006 Dec; 66(24):11649-58. PubMed ID: 17178859
[TBL] [Abstract][Full Text] [Related]
53. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?
Tassone P; Tagliaferri P; Rossi M; Gaspari M; Terracciano R; Venuta S
Eur J Cancer; 2006 Jul; 42(11):1530-8. PubMed ID: 16820292
[TBL] [Abstract][Full Text] [Related]
54. Bone lesions in molecular subtypes of multiple myeloma.
Robbiani DF; Chesi M; Bergsagel PL
N Engl J Med; 2004 Jul; 351(2):197-8. PubMed ID: 15247367
[No Abstract] [Full Text] [Related]
55. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
[TBL] [Abstract][Full Text] [Related]
56. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
57. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
58. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
60. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
